Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s115. https://doi.org/10.25251/skin.7.supp.115